{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:56Z","timestamp":1790805656015,"version":"4.1.0"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Medulloblastoma is a common malignant brain tumor of childhood. Human epidermal growth factor receptor 2 (HER2) is expressed by 40% of medulloblastomas and is a risk factor for poor outcome with current aggressive multimodal therapy. In contrast to breast cancer, HER2 is expressed only at low levels in medulloblastomas, rendering monoclonal antibodies ineffective. We determined if T cells grafted with a HER2-specific chimeric antigen receptor (CAR; HER2-specific T cells) recognized and killed HER2-positive medulloblastomas. Ex vivo, stimulation of HER2-specific T cells with HER2-positive medulloblastomas resulted in T-cell proliferation and secretion of IFN-\u03b3 and interleukin 2 (IL-2) in a HER2-dependent manner. HER2-specific T cells killed autologous HER2-positive primary medulloblastoma cells and medulloblastoma cell lines in cytotoxicity assays, whereas HER2-negative tumor cells were not killed. No functional difference was observed between HER2-specific T cells generated from medulloblastoma patients and healthy donors. In vivo, the adoptive transfer of HER2-specific T cells resulted in sustained regression of established medulloblastomas in an orthotopic, xenogenic severe combined immunodeficiency model. In contrast, delivery of nontransduced T cells did not change the tumor growth pattern. Adoptive transfer of HER2-specific T cells may represent a promising immunotherapeutic approach for medulloblastoma. [Cancer Res 2007;67(12):5957\u201364]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4309","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T09:26:18Z","timestamp":1181985978000},"page":"5957-5964","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells"],"prefix":"10.1158","volume":"67","author":[{"given":"Nabil","family":"Ahmed","sequence":"first","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshika","family":"Ratnayake","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Perlaky","sequence":"additional","affiliation":[{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"5Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried S.","family":"Wels","sequence":"additional","affiliation":[{"name":"12Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi B.","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"6Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"13St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. David","family":"Shine","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"8Neurosurgey,"},{"name":"9Neuroscience,"},{"name":"10Molecular and Cellular Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Weiss","sequence":"additional","affiliation":[{"name":"3The Breast Center, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"},{"name":"7Immunology,"},{"name":"11Molecular Virology and Microbiology, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"},{"name":"5Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"1Center for Cell and Gene Therapy,"},{"name":"2Texas Children's Cancer Center,"},{"name":"4Pediatrics,"},{"name":"7Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"2022061622281464400_B1","doi-asserted-by":"crossref","unstructured":"McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma\/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol\u20082002; 39: 190\u20134.","DOI":"10.1002\/mpo.10121"},{"key":"2022061622281464400_B2","doi-asserted-by":"crossref","unstructured":"Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol\u20082004; 31: 666\u201375.","DOI":"10.1053\/j.seminoncol.2004.07.009"},{"key":"2022061622281464400_B3","doi-asserted-by":"crossref","unstructured":"Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol\u20082004; 22: 984\u201393.","DOI":"10.1200\/JCO.2004.06.032"},{"key":"2022061622281464400_B4","doi-asserted-by":"crossref","unstructured":"Verneris MR, Arshi A, Edinger M, et al. Low levels of Her2\/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res\u20082005; 11: 4561\u201370.","DOI":"10.1158\/1078-0432.CCR-05-0157"},{"key":"2022061622281464400_B5","doi-asserted-by":"crossref","unstructured":"Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2\/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem\u20082004; 279: 53907\u201314.","DOI":"10.1074\/jbc.M407888200"},{"key":"2022061622281464400_B6","doi-asserted-by":"crossref","unstructured":"Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest\u20082002; 110: 983\u201392.","DOI":"10.1172\/JCI0215950"},{"key":"2022061622281464400_B7","doi-asserted-by":"crossref","unstructured":"Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol\u20081993; 151: 6577\u201382.","DOI":"10.4049\/jimmunol.151.11.6577"},{"key":"2022061622281464400_B8","doi-asserted-by":"crossref","unstructured":"Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A\u20081994; 91: 4318\u201322.","DOI":"10.1073\/pnas.91.10.4318"},{"key":"2022061622281464400_B9","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A\u20081993; 90: 720\u20134.","DOI":"10.1073\/pnas.90.2.720"},{"key":"2022061622281464400_B10","doi-asserted-by":"crossref","unstructured":"Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy\u20082003; 5: 211\u201326.","DOI":"10.1080\/14653240310001488"},{"key":"2022061622281464400_B11","doi-asserted-by":"crossref","unstructured":"Hombach A, Heuser C, Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther\u20082002; 2: 211\u201326.","DOI":"10.2174\/1566523024605573"},{"key":"2022061622281464400_B12","doi-asserted-by":"crossref","unstructured":"Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood\u20082002; 100: 3155\u201363.","DOI":"10.1182\/blood-2002-04-1041"},{"key":"2022061622281464400_B13","unstructured":"Pinthus JH, Waks T, Kaufman-Francis K, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res\u20082003; 63: 2470\u20136."},{"key":"2022061622281464400_B14","unstructured":"Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res\u20082003; 63: 140\u20138."},{"key":"2022061622281464400_B15","doi-asserted-by":"crossref","unstructured":"Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer\u20082001; 94: 228\u201336.","DOI":"10.1002\/ijc.1457"},{"key":"2022061622281464400_B16","doi-asserted-by":"crossref","unstructured":"Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther\u20082005; 12: 933\u201341.","DOI":"10.1016\/j.ymthe.2005.04.016"},{"key":"2022061622281464400_B17","doi-asserted-by":"crossref","unstructured":"Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood\u20082005; 105: 4247\u201354.","DOI":"10.1182\/blood-2004-11-4564"},{"key":"2022061622281464400_B18","doi-asserted-by":"crossref","unstructured":"Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol\u20081995; 69: 7430\u20136.","DOI":"10.1128\/jvi.69.12.7430-7436.1995"},{"key":"2022061622281464400_B19","doi-asserted-by":"crossref","unstructured":"Dotti G, Savoldo B, Pule M, et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood\u20082005; 105: 4677\u201384.","DOI":"10.1182\/blood-2004-08-3337"},{"key":"2022061622281464400_B20","doi-asserted-by":"crossref","unstructured":"Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood\u20082003; 101: 1905\u201312.","DOI":"10.1182\/blood-2002-05-1514"},{"key":"2022061622281464400_B21","doi-asserted-by":"crossref","unstructured":"Vera J, Savoldo B, Vigouroux S, et al. T-lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B-lymphocyte derived malignant cells. Blood\u20082006; 108: 3890\u20137.","DOI":"10.1182\/blood-2006-04-017061"},{"key":"2022061622281464400_B22","doi-asserted-by":"crossref","unstructured":"Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer\u20081995; 71: 473\u20137.","DOI":"10.1038\/bjc.1995.96"},{"key":"2022061622281464400_B23","doi-asserted-by":"crossref","unstructured":"Gilbertson RJ. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist\u20082005; 10: 508\u201317.","DOI":"10.1634\/theoncologist.10-7-508"},{"key":"2022061622281464400_B24","doi-asserted-by":"crossref","unstructured":"Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature\u20082004; 432: 396\u2013401.","DOI":"10.1038\/nature03128"},{"key":"2022061622281464400_B25","doi-asserted-by":"crossref","unstructured":"Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene\u20081999; 18: 2241\u201351.","DOI":"10.1038\/sj.onc.1202526"},{"key":"2022061622281464400_B26","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science\u20081989; 244: 707\u201312.","DOI":"10.1126\/science.2470152"},{"key":"2022061622281464400_B27","doi-asserted-by":"crossref","unstructured":"Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2\/HER-2 and family members. Breast Cancer Res\u20082001; 3: 385\u20139.","DOI":"10.1186\/bcr327"},{"key":"2022061622281464400_B28","unstructured":"Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene\u20081990; 5: 953\u201362."},{"key":"2022061622281464400_B29","unstructured":"Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res\u20082003; 63: 140\u20138."},{"key":"2022061622281464400_B30","unstructured":"Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu-overexpressing metastatic breast cancer. Semin Oncol\u20081999; 26: 78\u201383."},{"key":"2022061622281464400_B31","doi-asserted-by":"crossref","unstructured":"Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother\u20081993; 37: 255\u201363.","DOI":"10.1007\/BF01518520"},{"key":"2022061622281464400_B32","doi-asserted-by":"crossref","unstructured":"Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell\u20082007; 11: 69\u201382.","DOI":"10.1016\/j.ccr.2006.11.020"},{"key":"2022061622281464400_B33","unstructured":"Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Curr Hematol Rep\u20082004; 3: 290\u20137."},{"key":"2022061622281464400_B34","doi-asserted-by":"crossref","unstructured":"Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res\u20082004; 64: 9160\u20136.","DOI":"10.1158\/0008-5472.CAN-04-0454"},{"key":"2022061622281464400_B35","doi-asserted-by":"crossref","unstructured":"Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol\u20082006; 16: 333\u201343.","DOI":"10.1016\/j.semcancer.2006.07.008"},{"key":"2022061622281464400_B36","unstructured":"Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res\u20082003; 9: 3294\u2013302."},{"key":"2022061622281464400_B37","unstructured":"Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res\u20082000; 6: 2209\u201318."},{"key":"2022061622281464400_B38","doi-asserted-by":"crossref","unstructured":"Walker PR, Calzascia T, Dietrich PY. All in the head: obstacles for immune rejection of brain tumours. Immunology\u20082002; 107: 28\u201338.","DOI":"10.1046\/j.1365-2567.2002.01507.x"},{"key":"2022061622281464400_B39","doi-asserted-by":"crossref","unstructured":"Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol\u20082002; 169: 5780\u20136.","DOI":"10.4049\/jimmunol.169.10.5780"},{"key":"2022061622281464400_B40","doi-asserted-by":"crossref","unstructured":"Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol\u20082004; 172: 104\u201313.","DOI":"10.4049\/jimmunol.172.1.104"},{"key":"2022061622281464400_B41","doi-asserted-by":"crossref","unstructured":"Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood\u20082005; 105: 3087\u201393.","DOI":"10.1182\/blood-2004-09-3737"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/12\/5957\/2568794\/5957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/12\/5957\/2568794\/5957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:30:31Z","timestamp":1683876631000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/12\/5957\/533041\/Regression-of-Experimental-Medulloblastoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2007,6,15]]},"published-print":{"date-parts":[[2007,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4309","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}